• Enesi Pharma Enters Agreement with National Institutes of Health to Evaluate ImplaVax^®-enabled Flu Vaccines

  19th October 2021

  OXFORD, UK – 19 October 2021 – Enesi Pharma (“Enesi”), an innovative biotechnology company developing next-generation vaccination products targeting infectious diseases and emergent threat pathogens, enabled by its ImplaVax® technologies, has entered into an agreement with the US National Institute of Health’s (NIH) National Institute of Allergy and Infectious Diseases (NIAID) to test a novel… read more

• Enesi Pharma appoints Elizabeth Eagling-Vose, MBA, as Senior Vice President, Operations

  7th September 2021

  Experienced leader in clinical operations joins Enesi to drive the development of vaccine programmes enabled using its innovative ImplaVax® solid dose, needle-free technology Oxford, UK, 7 September 2021 – Enesi Pharma Ltd (“Enesi”), an innovative biotechnology company developing next-generation vaccination products, targeting infectious diseases and emergent threat pathogens, enabled by its world leading ImplaVax® technologies,… read more

• Enesi Pharma’s ImplaVax^® Technology Platform Spotlighted in Medical Device Developments Article on Elimination of Cold Chain Logistics

  22nd June 2021

  OXFORD, UK – 22 June 2021 – Enesi Pharma is pleased to acknowledge Lynette Eyb’s excellent article ‘A Total Meltdown’ in Medical Device Developments’  where the potential of Enesi’s proprietary ImplaVax® formulation and delivery technologies are discussed. The Article ‘A Total Meltdown‘ highlights how next generation vaccination technologies such as ImplaVax® needle-free, thermally stable unit… read more

• Enesi Pharma’s ImplaVax^®-Enabled, Solid-Dose Recombinant Classical Swine Fever (CSF) Vaccine Produces Immune Responses Superior to Liquid Vaccine

  6th May 2021

  Second positive study in important animal health indications using different vaccine constructs demonstrates potential of ImplaVax®-enabled needle-free thermally stable solid-dose vaccination platform with read-through to human health OXFORD, UK – 6 May 2021 – Enesi Pharma (“Enesi”), an innovative biotechnology company developing next-generation vaccination products targeting infectious diseases and emergent threat pathogens enabled by its… read more

• Enesi Pharma Achieves Key Milestone in Development of Thermostable Solid-dose Live Vaccines against Measles and Rubella

  5th May 2021

  OXFORD, UK – 5 May 2021 – Enesi Pharma (“Enesi”), an innovative biotechnology company developing next-generation vaccination products targeting infectious diseases and emergent threat pathogens enabled by its ImplaVax® technologies, announces it has achieved a key milestone in its project to develop needle-free thermostable unit solid-dose live vaccines with retained activity against Measles and Rubella…. read more

• Enesi Pharma Achieves Preclinical Proof-of-Concept with ImplaVax®-Enabled Pandemic Influenza Vaccine

  4th May 2021

  Innovative needle-free injectable unit solid-dose presentation of recombinant H7N9 pandemic flu vaccine, created using Enesi’s ImplaVax® technology, generated immune responses comparable with liquid vaccine and demonstrated excellent thermal stability at temperatures up to 40°C for six months.   OXFORD, UK – 4 May 2021 – Enesi Pharma (“Enesi”), an innovative biotechnology company developing next-generation vaccination… read more

• Enesi Pharma to Present at World Vaccine Congress 2021 Virtual Meeting

  26th April 2021

  OXFORD, UK – 26 April 2021 – Enesi Pharma (“Enesi”), an innovative biotechnology company developing next-generation vaccination products targeting infectious diseases and emergent threat pathogens enabled by its ImplaVax® technologies, announces that its CEO, David Hipkiss will give a presentation at the upcoming World Vaccine Congress 2021 Virtual meeting (4-6 May 2021), which this year… read more

• Enesi Pharma’s ImplaVax^® Solid-Dose Needle-free Vaccination Technology Featured in the Wall Street Journal

  5th March 2021

  Enesi Pharma’s CEO, David Hipkiss, spoke to WSJ reporter Jason Douglas about Enesi’s ImplaVax® solid-dose needle-free vaccination technology as part of a larger feature investigating how the COVID-19 pandemic has spurred innovation into new vaccination technologies that use alternative approaches to traditional needle and syringe delivery. The story, published on 3rd March 2021, can be… read more

• Enesi Pharma ImplaVax^® Solid Dose Needle-free Vaccination Technology Featured on Leading News Channel in Japan

  19th February 2021

  Enesi Pharma recently hosted a crew from Asahi TV, one of Japan’s leading TV channels, at its Oxford, UK facility to talk about the potential of its ImplaVax® solid dose needle-free vaccination technology. The conversation coincided with the approval of the Pfizer/BioNTech COVID-19 vaccine Comirnaty® in Japan and potential dose-wasting issues linked to the type… read more

• Enesi Pharma and Imperial College London Collaborate to Develop Thermostable RNA Vaccines with Potential to Eliminate Cold Chain and Transform Global Vaccination Logistics for COVID-19

  18th December 2020

  OXFORD and LONDON, UK – 18 December 2020 – Enesi Pharma (“Enesi”), an innovative biotechnology company developing next-generation vaccination products targeting infectious diseases and emergent threat pathogens enabled by its ImplaVax® technologies, announces it is collaborating with Prof. Robin Shattock, a leading infectious disease and vaccine expert, and his group at Imperial College London (“Imperial”),… read more